References

biopreparat

БИОпрепараты. Профилактика, диагностика, лечение

Biological Products. Prevention, Diagnosis, Treatment

2221-996X2619-1156

Scientific Centre for Expert Evaluation of Medicinal Products

10.30895/2221-996X-2018-18-2-81-91

biopreparat-134

Research Article

ОБЗОРЫ

REVIEWS

Адъюванты на основе углеводов для производства вакцин

Carbohydrate-Based Adjuvants for Vaccine Production

Курашова

С. С.

Kurashova

S. S.

Младший научный сотрудник

домовладение 8, стр. 1, поселок Института полиомиелита, поселение Московский, Москва, 108819, Российская Федерация

Junior Researcher

8/1 housing estate of the Institute of Poliomyelitis, «Moskovsky» settlement, Moscow 108819, Russian Federation

Дзагурова

Т. К.

Dzagurova

T. K.

Руководитель лаборатории геморрагических лихорадок, д-р мед. наук

Head of the Laboratory of Hemorrhagic Fevers. Doctor of Medical Sciences

8/1 housing estate of the Institute of Poliomyelitis, «Moskovsky» settlement, Moscow 108819, Russian Federation

Ишмухаметов

А. А.

Ishmukhametov

A. A.

Генеральный директор, д-р мед. наук

ул. Трубецкая, д. 8, стр. 2, Москва, 119991, Российская Федерация

General Director. Doctor of Medical Sciences

8/1 housing estate of the Institute of Poliomyelitis, «Moskovsky» settlement, Moscow 108819, Russian Federation

8/2 Trubetskaya St, Moscow 119991, Russian Federation

Егорова

М. С.

Egorova

M. S.

Старший научный сотрудник, канд. биол. наук

Senior Researcher. Candidate of Biological Sciences

8/1 housing estate of the Institute of Poliomyelitis, «Moskovsky» settlement, Moscow 108819, Russian Federation

Баловнева

М. В.

Balovneva

M. V.

Старший научный сотрудник, канд. биол. наук

Senior Researcher. Candidate of Biological Sciences

8/1 housing estate of the Institute of Poliomyelitis, «Moskovsky» settlement, Moscow 108819, Russian Federation

Соцкова

С. Е.

Sotskova

S. E.

Директор по организационно-методической работе

Director in Charge of Organisational and Methodical Issues

8/1 housing estate of the Institute of Poliomyelitis, «Moskovsky» settlement, Moscow 108819, Russian Federation

Ткаченко

Е. А.

Tkachenko

E. A.

Руководитель научного направления, д-р мед. наук, профессор

ул. Трубецкая, д. 8, стр. 2, Москва, 119991, Российская Федерация

Scientific Supervisor. Doctor of Medical Sciences, Professor

8/1 housing estate of the Institute of Poliomyelitis, «Moskovsky» settlement, Moscow 108819, Russian Federation

8/2 Trubetskaya St, Moscow 119991, Russian Federation

evgeniytkach@mail.ru

Федеральное государственное бюджетное научное учреждение «Федеральный научный центр исследований и разработки иммунобиологических препаратов им. М.П. Чумакова РАН»РоссияChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of SciencesRussian Federation

Федеральное государственное бюджетное научное учреждение «Федеральный научный центр исследований и разработки иммунобиологических препаратов им. М.П. Чумакова РАН» Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской ФедерацииРоссияChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences Sechenov First Moscow State Medical UniversityRussian Federation

2018

21062018

1828191

2018

Курашова С.С., Дзагурова Т.К., Ишмухаметов А.А., Егорова М.С., Баловнева М.В., Соцкова С.Е., Ткаченко Е.А.

Kurashova S.S., Dzagurova T.K., Ishmukhametov A.A., Egorova M.S., Balovneva M.V., Sotskova S.E., Tkachenko E.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.biopreparations.ru/jour/article/view/134

Общепризнанным способом усиления иммуногенности вакцин является добавление в их состав адъювантов. Последние характеризуются большим разнообразием, поэтому подбор адъюванта осуществляется путем сравнения эффективности адъювантов на моделях животных, а также оценки их безопасности и переносимости. Среди множества различных групп веществ, потенциально обладающих адъювантными свойствами, сравнительно мало внимания уделяют адъювантам на основе углеводов, несмотря на то, что они совместимы с живыми векторными вакцинами, безопасны, хорошо переносятся, а их производство не отличается трудоемкостью. Благодаря этим преимуществам применение именно таких адъювантов в сочетании с любым типом вакцины, в том числе с векторной или ДНК-вакциной, может быть наиболее целесообразным и перспективным. В настоящем обзоре рассмотрены различные типы углеводных адъювантов и механизмы, определяющие их эффективность.

Addition of adjuvants is a generally recognized method of enhancing the immunogenicity of vaccines. There is a large variety of adjuvants, therefore the choice of an adjuvant is based on the comparison of adjuvants efficacy in animal models, as well as assessment of their safety and tolerability. There are many different groups of substances that may have adjuvant properties, but relatively little attention is paid to carbohydrate-based adjuvants, despite the fact that they are compatible with live vector vaccines, safe, well tolerated, and their production is not laborious. Thanks to these advantages the use of these particular adjuvants in combination with any type of vaccine, including vector vaccines and DNA vaccines, may be most appropriate and promising. This review examines various types of carbohydrate adjuvants and the mechanisms that determine their efficacy.

адъювантгуморальный иммунитетполисахаридыиммуногенностьбезопасность вакцинживые векторные вакциныиммунитетиммунологическая активность полисахаридов

adjuvanthumoral immunitypolysaccharidesimmunogenicityvaccine safetylive vector vaccinesimmunityimmunological activity of polysaccharides

References1

Дранник ГН. Клиническая иммунология и аллергология. Одесса: АстроПринт; 1999. [Drannik GN. Clinical Immunology and Allergology. Odessa: AstroPrint; 1999 (in Russ.)]

Дитятковская ЕМ, Василевская ИВ, Кийко ЛА. Аллергология и иммунология. Днепропетровск: ФПО ДГМА; 2003. [Dityatkovskaya EM, Vasilevskaya IV, Kijko LА. Allergology and Immunology. Dnepropetrovsk: FPO DGMA; 2003 (in Russ.)]

Хаитов РМ. Иммунология: структура и функции иммунной системы: учебное пособие. М.: ГЭОТАР-Медиа; 2013. [Khaitov RM. Immunology: Structure and Functions of the Immune System: Textbook. Moscow: GEOTAR-Media; 2013 (in Russ.)]

Vogel FR. Adjuvants in Perspective. Dev Biol Stand. 1998;92:241–8.

Vogel FR. Improving Vaccine Performance with Adjuvants. Clin Infect Dis. 2000;30 Suppl 3:S266–70. DOI: 10.1086/313883

Исаенко ЕЮ, Бабич ЕМ, Елисеева ИВ, Ждамарова ЛА, Белозерский ВИ, Колпак СА. Адъюванты в современной вакцинологии. Аннали Мечниковського інституту 2013;(4):5– 21. [Isaenko YeYu, Babych YeM, Yelyseyeva IV, Zhdamarova LA, Belozersky VI, Kolpak SA. Adjuvants in Modern Vaccinology. Annali Mechnikovskogo іnstitutu 2013;(4):5–21 (in Russ.)]

Gupta RK, Siber GR. Adjuvants for Human Vaccines — Current Status, Problems and Future Prospects. Vaccine 1995;13(14):1263–76. DOI: 10.1016/0264-410X(95)00011-O

O’Hagan DT, ed. Vaccine Adjuvants: Preparation Methods and Research Protocols. Totowa NJ: Humana Press; 2000.

Козлов ВГ, Ожерелков СВ, Санин АВ, Кожевникова ТН. Адъюванты в современной медицине и ветеринарии. Журнал микробиологии, эпидемиологии и иммунобиологии 2014;(1):91–102. [Kozlov VG, Ozherelkov SV, Sanin AV, Kozhevnikova TN. Adjuvants in Modern Medicine and Veterinary. Zhurnal mikrobiologii, epidemiologii, i immunobiologii 2014;(1):91– 102 (in Russ.)]

Суворов АН, Леонтьева ГФ, Мерингова ЛФ, Грабовская КБ, Гупалова ТВ, Воробьева ЕИ и др. Влияние различных адъювантов на иммуногенность компонентов вакцины против стрептококков группы B. Медицинская Иммунология 2008;10(2-3):215–22. [Suvorov AN, Leontyeva GF, Meringova LF, Grabovskaya KB, Gupalova TV, Vorobyeva EI, et al. Effects of Different Adjuvants upon Immunogenicity of Anti-Group B Streptococcal Vaccine Components. Medicinskaya Immunologiya 2008;10(2-3):215–22 (in Russ.)]

Aguilar JC, Rodriguez EG. Vaccine Adjuvants Revisited. Vaccine 2007;25(19):3752–62. DOI: 10.1016/j.vaccine.2007.01.111

McKee AS, Marrack P. Old and New Adjuvants. Curr Opin Immunol. 2017;47:44–51. DOI: 10.1016/j.coi.2017.06.005

Savelkoul HF, Ferro VA, Strioga MM, Schijns VE. Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines. Vaccines (Basel) 2015;3(1):148–71. DOI: 10.3390/vaccines3010148

Petrovsky N, Larena M, Siddharthan V, Prow NA, Hall RA, Lobigs M, Morrey J. An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection Against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing Antibody. J Virol. 2013;87(18):10324–33. DOI: 10.1128/JVI.00480-13

Passeri E, Villa C, Couette M, Itti E, Brugieres P, Cesaro P, et al. Long-Term Follow-up of Cognitive Dysfunction in Patients with Aluminum Hydroxide-Induced Macrophagic Myofasciitis (MMF). J Inorg Biochem. 2011;105(11):1457–63. DOI: 10.1016/j.jinorgbio.2011.08.006

Ciabattini A, Pettini E, Fiorino F, Pastore G, Andersen P, Pozzi G, Medaglini D. Modulation of Primary Immune Response by Different Vaccine Adjuvants. Front Immunol. 2016;7:427. DOI: 10.3389/fimmu.2016.00427

Petrovsky N. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. Drug Saf. 2015;38(11):1059–74. DOI: 10.1007/s40264-015-0350-4

Cooper PD, Carter M. Anti-Complementary Action of Polymorphic «Solubility Forms» of Particulate Inulin. Mol Immunol. 1986;23(8):895–901.

Cooper PD, Barclay TG, Ginic-Markovic M, Petrovsky N. The Polysaccharide Inulin is Characterized by an Extensive Series of Periodic Isoforms with Varying Biological Actions. Glycobiology 2013;23(10):1164–74. DOI: 10.1093/glycob/cwt053

Cooper PD, Petrovsky N. Delta Inulin: A Novel, Immunologically Active, Stable Packing Structure Comprising β-D-[2 → 1] poly(fructo-furanosyl) α-D-glucose Polymers. Glycobiology 2011;21(5):595–606. DOI: 10.1093/glycob/cwq201

Honda-Okubo Y, Saade F, Petrovsky N. Advax™, a Polysaccharide Adjuvant Derived from Delta Inulin, Provides Improved Influenza Vaccine Protection through Broad-Based Enhancement of Adaptive Immune Responses. Vaccine 2012;30(36):5373–81. DOI: 10.1016/j.vaccine.2012.06.021

Larena M, Prow NA, Hall RA, Petrovsky N, Lobigs M. JEADVAX Vaccine Protection against Japanese Encephalitis Virus Mediated by Memory B Cells in the Absence of CD8(+) T Cells and Pre-Exposure Neutralizing Antibody. J Virol. 2013;87(8):4395–402. DOI: 10.1128/JVI.03144-12

Saade F, Honda-Okubo Y, Trec S, Petrovsky N. A Novel Hepatitis B Vaccine Containing Advax™, a Polysaccharide Adjuvant Derived from Delta Inulin, Induces Robust Humoral and Cellular Immunity with Minimal Reactogenicity in Preclinical Testing. Vaccine 2013;31(15):1999– 2007. DOI: 10.1016/j.vaccine.2012.12.077

Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, et al. Induction of Mucosal and Systemic Antibody and T-cell Responses Following Prime-Boost Immunization with Novel Adjuvanted Human Immunodeficiency Virus-1-vaccine Formulations. J Gen Virol. 2011;92(Pt 1):128–40. DOI: 10.1099/vir.0.023242-0

Layton RC, Petrovsky N, Gigliotti AP, Pollock Z, Knight J, Donart N, et al. Delta Inulin Polysaccharide Adjuvant Enhances the Ability of Split-Virion H5N1 Vaccine to Protect against Lethal Challenge in Ferrets. Vaccine 2011;29(37):6242–51. DOI: 10.1016/j.vaccine.2011.06.078

Lobigs M, Pavy M, Hall RA, Lobigs P, Cooper P, Komiya T, et al. An Inactivated Vero Cell- Grown Japanese Encephalitis Vaccine Formulated with Advax, a Novel Inulin-Based Adjuvant, Induces Protective Neutralizing Antibody against Homologous and Heterologous Flaviviruses. J Gen Virol. 2010;91(Pt 6):1407–17. DOI: 10.1099/vir.0.019190-0

Eckersley AM, Petrovsky N, Kinne J, Wernery R, Wernery U. Improving the Dromedary Antibody Response: the Hunt for the Ideal Camel Adjuvant. J Camel Pract Res. 2011;18(1):35–46.

Gordon DL, Sajkov D, Woodman RJ, Honda-Okubo Y, Cox MM, Heinzel S, Petrovsky N. Randomized Clinical Trial of Immunogenicity and Safety of a Recombinant H1N1/2009 Pandemic Influenza Vaccine Containing Advax™ Polysaccharide Adjuvant. Vaccine 2012;30(36):5407–16. DOI: 10.1016/j.vaccine.2012.06.009

Houston WE, Crabbs CL, Kremer RJ, Springer JW. Adjuvant Effects of Diethylaminoethyl- dextran. Infect Immun. 1976;13(6):1559–62.

Kaistha J, Sokhey J, Singh S, Kumar S, John PC, Sharma NC. Adjuvant Effect of DEAE- dextran and Tetanus Toxoid on Whole Cell Heat Inactivated Phenol Preserved Typhoid Vaccine. Indian J Pathol Microbiol. 1996;39(4):287–92.

Bachelder EM, Beaudette TT, Broaders KE, Frechet JM, Albrecht MT, Mateczun AJ, et al. In vitro Analysis of Acetalated Dextran Microparticles as a Potent Delivery Platform for Vaccine Adjuvants. Mol Pharm. 2010;7(3):826–35. DOI: 10.1021/mp900311x

Schorlemmer HU, Bitter-Suermann D, Allison AC. Complement Activation by the Alternative Pathway and Macrophage Enzyme Secretion in the Pathogenesis of Chronic Inflammation. Immunology 1977;32(6):929–40.

Lamkanfi M, Malireddi RK, Kanneganti TD. Fungal Zymosan and Mannan Activate the Cryopyrin Inflammasome. J Biol Chem. 2009;284(31):20574–81. DOI: 10.1074/jbc.M109.023689

Morikawa K, Takeda R, Yamazaki M, Mizuno D. Induction of Tumoricidal Activity of Polymorphonuclear Leukocytes by a Linear beta-1,3-D-glucan and Other Immunomodulators in Murine Cells. Cancer Res. 1985;45(4):1496–501.

Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M, et al. Zymosan Enhances the Immune Response to DNA Vaccine for Human Immunodeficiency Virus Type-1 through the Activation of Complement System. Immunology 2001;103(1):98–105.

Jeannin JF, Lagadec P, Pelletier H, Reisser D, Olsson NO, Chihara G, Martin F. Regression Induced by Lentinan, of Peritoneal Carcinomatoses in a Model of Colon Cancer in Rat. Int J Immunopharmacol. 1988;10(7):855–61.

Wang J, Zhou ZD, Xia DJ. Study on Effect of Lentinan in Enhancing Anti-Tumor Action of Dendritic Cytoma Vaccine and Its Mechanism. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007;27(1):60–4.

Guo Z, Hu Y, Wang D, Ma X, Zhao X, Zhao B, et al. Sulfated Modification Can Enhance the Adjuvanticity of Lentinan and Improve the Immune Effect of ND Vaccine. Vaccine 2009;27(5):660–5. DOI: 10.1016/j.vaccine.2008.11.038

Mohagheghpour N, Dawson M, Hobbs P, Judd A, Winant R, Dousman L, et al. Glucans as Immunological Adjuvants. Adv Exp Med Biol. 1995;383:13–22.

Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM. Robust Stimulation of Humoral and Cellular Immune Responses Following Vaccination with Antigen-Loaded Beta-Glucan Particles. MBio. 2010;1(3):e00164–10. DOI: 10.1128/mBio.00164-10

Takahara K, Yashima Y, Omatsu Y, Yoshida H, Kimura Y, Kang YS, et al. Functional Comparison of the Mouse DCSIGN, SIGNR1, SIGNR3 and Langerin, C-type Lectins. Int Immunol. 2004;16(6):819–29. DOI: 10.1093/intimm/dxh084

Sheng KC, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, Apostolopoulos V. Mannan Derivatives Induce Phenotypic and Functional Maturation of Mouse Dendritic Cells. Immunology 2006;118(3):372–83. DOI: 10.1111/j.1365-2567.2006.02384.x

Vassilaros S, Tsibanis A, Tsikkinis A, Pietersz GA, McKenzie IF, Apostolopoulos V. Up to 15- year Clinical Follow-up of a Pilot Phase III Immunotherapy Study in Stage II Breast Cancer Patients using Oxidized Mannan- MUC1. Immunotherapy 2013;5(11):1177–82. DOI: 10.2217/imt.13.126

Katsara M, Yuriev E, Ramsland PA, Tselios T, Deraos G, Lourbopoulos A, et al. Altered Peptide Ligands of Myelin Basic Protein (MBP87-99) Conjugated to Reduced Mannan Modulate Immune Responses in Mice. Immunology 2009;128(4):521–33. DOI: 10.1111/j.1365-2567.2009.03137.x

Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, et al. Mannan-Abeta28 Conjugate Prevents Abeta-plaque Deposition, but Increases Microhemor- rhages in the Brains of Vaccinated Tg2576 (APPsw) Mice. J Neuroinflammation. 2008;5:42. DOI: 10.1186/1742-2094-5-42

Kawakami S, Sato A, Nishikawa M, Yamashita F, Hashida M. Mannose Receptor-Mediated Gene Transfer into Macrophages using Novel Mannosylated Cationic Liposomes. Gene Ther. 2000;7(4):292–9. DOI: 10.1038/sj.gt.3301089

Lu Y, Kawakami S, Yamashita F, Hashida M. Development of an Antigen-Presenting Cell- Targeted DNA Vaccine Against Melanoma by Mannosylated Liposomes. Biomaterials 2007;28(21):3255–62. DOI: 10.1016/j.biomaterials.2007.03.028

Zhao Z, Yao Y, Ding Z, Chen X, Xie K, Luo Y, et al. Antitumour Immunity Mediated by Mannan-Modified Adenovirus Vectors Expressing VE-cadherin. Vaccine 2011;29(25):4218–24. DOI: 10.1016/j.vaccine.2011.03.109

Arca HC, Gunbeyaz M, Senel S. Chitosan-based Systems for the Delivery of Vaccine Antigens. Expert Rev Vaccines 2009;8(7):937–53. DOI: 10.1586/erv.09.47

Ghendon Y, Markushin S, Vasiliev Y, Akopova I, Koptiaeva I, Krivtsov G, et al. Evaluation of Properties of Chitosan as an Adjuvant for Inactivated Influenza Vaccines Administered Parenterally. J Med Virol. 2009;81(3):494–506. DOI: 10.1002/jmv.21415

Chang H, Li X, Teng Y, Liang Y, Peng B, Fang F, Chen Z. Comparison of Adjuvant Efficacy of Chitosan and Aluminum Hydroxide for Intraperitoneally Administered Inactivated Influenza H5N1 Vaccine. DNA Cell Biol. 2010;29(9):563–8. DOI: 10.1089/dna.2009.0977

Kotze AF, Luessen HL, de Leeuw BJ, de Boer BG, Verhoef JC, Junginger HE. N-trimethyl Chitosan Chloride as a Potential Absorption Enhancer Across Mucosal Surfaces: In Vitro Evaluation in Intestinal Epithelial Cells (Caco-2). Pharm Res. 1997;14(9):1197–202.

Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, Giudice GD. The Concomitant Use of the LTK63 Mucosal Adjuvant and of Chitosan-Based Delivery System Enhances the Immunogenicity and Efficacy of Intranasally Administered Vaccines. Vaccine 2003;21(25– 26):3837–44.

Khatri K, Goyal AK, Gupta PN, Mishra N, Vyas SP. Plasmid DNA Loaded Chitosan Nanoparticles for Nasal Mucosal Immunization Against Hepatitis B. Int J Pharm. 2008;354(1– 2):235–41. DOI: 10.1016/j.ijpharm.2007.11.027

Gogev S, de Fays K, Versali MF, Gautier S, Thiry E. Glycol Chitosan Improves the Efficacy of Intranasally Administrated Replication Defective Human Adenovirus Type 5 Expressing Glycoprotein D of Bovine Herpesvirus 1. Vaccine 2004;22(15– 16):1946–53. DOI: 10.1016/j.vaccine.2003.11.011

Rauw F, Gardin Y, Palya V, Anbari S, Lemaire S, Boschmans M, et al. Improved Vaccination Against Newcastle Disease by an in Ovo Recombinant HVT-ND Combined with an Adjuvanted Live Vaccine at Day-Old. Vaccine 2010;28(3):823–33. DOI: 10.1016/j.vaccine.2009.10.049

Wang X, Zhang W, Liu F, Zheng M, Zheng D, Zhang T, et al. Intranasal Immunization with Live Attenuated Influenza Vaccine Plus Chitosan as an Adjuvant Protects Mice against Homologous and Heterologous Virus Challenge. Arch Virol. 2012;157(8):1451–61. DOI: 10.1007/s00705-012-1318-7

El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, et al. Adjuvanted Intranasal Norwalk Virus-Like Particle Vaccine Elicits Antibodies and Antibody- Secreting Cells that Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues. J Infect Dis. 2010;202(11):1649–58. DOI: 10.1086/657087

Lemke CD, Graham JB, Geary SM, Zamba G, Lubaroff DM, Salem AK. Chitosan is a Surprising Negative Modulator of Cytotoxic CD8+ T Cell Responses Elicited by Adenovirus Cancer Vaccines. Mol Pharm. 2011;8(5):1652–61. DOI: 10.1021/mp100464y

Doz E, Rose S, Nigou J, Gilleron M, Puzo G, Erard F, et al. Acylation Determines the Toll-Like Receptor (TLR)- Dependent Positive Versus TLR2-, Mannose Receptor-, and SIGNR1- Independent Negative Regulation of Proinflammatory Cytokines by Mycobacterial Lipomannan. J Biol Chem. 2007; 282(36):26014–25. DOI: 10.1074/jbc.M702690200

Yamamura Y, Azuma I, Sugimura K, Yamawaki M, Uemiya M. Adjuvant Activity of 6-O- mycoloyl-N-acetylmuramuyl-Lalanyl- D-isoglutamine. Gan 1976;67(6):867–77.

Azuma I, Okumura H, Saiki I, Kiso M, Hasegawa A, Tanio Y, Yamamura Y. Adjuvant Activity of Carbohydrate Analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine on the Induction of Delayed-Type Hypersensitivity to Azobenzenearsonate- N-acetyl-L-tyrosine in Guinea Pigs. Infect Immun. 1981;33(3):834–39.

Masihi KN, Lange W, Brehmer W, Ribi E. Immunobiological Activities of Nontoxic Lipid A: Enhancement of Nonspecific Resistance in Combination with Trehalose Dimycolate against Viral Infection and Adjuvant Effects. Int J Immunopharmacol. 1986;8(3):339–45.

Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, Mitchell TC. Selective Activation of the p38 MAPK Pathway by Synthetic Monophosphoryl Lipid A. J Biol Chem. 2009;284(46):31982–91. DOI: 10.1074/jbc.M109.046383

Schiller JT, Castellsague X, Villa LL, Hildesheim A. An Update of Prophylactic Human Papillomavirus L1 Virus-Like Particle Vaccine Clinical Trial Results. Vaccine 2008;26(Suppl 10):K53–K61. DOI: 10.1016/j.vaccine.2008.06.002

Quan FS, Ko EJ, Kwon YM, Joo KH, Compans RW, Kang SM. Mucosal Adjuvants for Influenza Virus-Like Particle Vaccine. Viral Immunol. 2013;26(6):385–95. DOI: 10.1089/vim.2013.0013

Lacaille-Dubois M-A. Bioactive Saponins with Cancer Related and Immunomodulatory Activity: Recent Developments. In: Atta-ur-Rahman, ed. Bioactive Natural Products. Amsterdam: Elsevier; 2005. Vol. 32, Part L, P. 209–246. DOI: 10.1016/s1572-5995(05)80057-2.

Kensil CR, Wu JY, Soltysik S. Structural and Immunological Characterization of the Vaccine Adjuvant QS-21. Pharm Biotechnol. 1995;6:525–41.

Pham HL, Ross BP, McGeary RP, Shaw PN, Hewavitharana AK, Davies NM. Saponins from Quillaja Saponaria Molina: Isolation, Characterization and Ability to Form Immuno Stimulatory Complexes (ISCOMs). Curr Drug Deliv. 2006;3(4):389–97.

Quenelle DC, Collins DJ, Rice TL, Prichard MN, Marciani DJ, Kern ER. Effect of an Immune Enhancer, GPI-0100, on Vaccination with Live Attenuated Herpes Simplex Virus (HSV) Type 2 or Glycoprotein D on Genital HSV-2 Infections of Guinea Pigs. Antiviral Res. 2008;80(2):223–4. DOI:

1016/j.antiviral.2008.05.011

Ragupathi G, Coltart DM, Williams LJ, Koide F, Kagan E, Allen J, et al. On the Power of Chemical Synthesis: Immunological Evaluation of Models for Multiantigenic Carbohydrate- Based Cancer Vaccines. Proc Natl Acad Sci U S A 2002;99(21):13699–704. DOI: 10.1073/pnas.202427599

Raphael TJ, Kuttan G. Effect of Naturally Occurring Triterpenoids Glycyrrhizic Acid, Ursolic Acid, Oleanolic Acid and Nomilin on the Immune System. Phytomedicine 2003;10(6–7):483–9. DOI: 10.1078/094471103322331421

Newman MJ, Wu JY, Gardner BH, Anderson CA, Kensil CR, Recchia J, et al. Induction of Cross-Reactive Cytotoxic T-lymphocyte Responses Specific for HIV-1 gp120 Using Saponin Adjuvant (QS-21) Supplemented Subunit Vaccine Formulations. Vaccine 1997;15(9):1001–7.

Sasaki S, Sumino K, Hamajima K, Fukushima J, Ishii N, Kawamoto S, et al. Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated with QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes. J Virol. 1998;72(6):4931–9.

Lee JK, Lee MK, Yun YP, Kim Y, Kim JS, Kim YS, et al. Acemannan Purified from Aloe Vera Induces Phenotypic and Functional Maturation of Immature Dendritic Cells. Int Immunopharmacol. 2001;1(7):1275–84.

Bohana-Kashtan O, Ziporen L, Donin N, Kraus S, Fishelson Z. Cell Signals Transduced by Complement. Mol Immunol. 2004;41(6–7):583–97. DOI: 10.1016/j.molimm.2004.04.007

Rawal N, Rajagopalan R, Salvi VP. Stringent Regulation of Complement Lectin Pathway C3/C5 Convertase by C4bbinding Protein (C4BP). Mol Immunol. 2009;46(15):2902–10. DOI: 10.1016/j.molimm.2009.07.006

Weston SA, Parish CR. Modification of Lymphocyte Migration by Mannans and Phosphomannans. Different Carbohydrate Structures Control Entry of Lymphocytes into Spleen and Lymph Nodes. J Immunol. 1991;146(12):4180–6.

Dong SF, Chen JM, Zhang W, Sun SH, Wang J, Gu JX, et al. Specific Immune Response to HBsAg is Enhanced by Beta-glucan Oligosaccharide Containing an alpha-(1–>3)linked Bond and Biased towards M2/Th2. Int Immunopharmacol. 2007;7(6):725–33. DOI: 10.1016/j.intimp.2007.01.004

Petrovsky N, Cooper PD. Advax™, a Novel Microcrystalline Polysaccharide Particle Engineered from Delta Inulin, Provides Robust Adjuvant Potency together with Tolerability and Safety. Vaccine 2015;33(44):5920–6. DOI: 10.1016/j.vaccine.2015.09.030

The authors declare that there are no conflicts of interest present.